“CANCER SIGNAL NOT detected.” That was the happy finding of my Galleri multi-cancer early detection (MCED) blood test from the Silicon Valley biotech company GRAIL. The Galleri test presages an emerging wave of new precision biomedical tests produced by a panoply of biotech startups.
GRAIL’s MCED test analyzes DNA shed by both normal and cancerous cells into a person’s bloodstream, looking for telltale epigenetic changes